How to Read Peptide Research: A Practical Guide

Why Learning to Read Studies Matters in the Peptide Space

The peptide market has a specific problem: the gap between what studies show and what vendors claim is enormous. A rodent wound-healing study that found BPC-157 accelerated tendon repair in Sprague-Dawley rats becomes, by the time it reaches a product page, definitive evidence that BPC-157 will heal your injury in four weeks. That transformation is not science — it is marketing.

The skill of reading studies critically closes that gap. You do not need a PhD in biochemistry to do this. You need a consistent framework for evaluating what kind of evidence exists, how it was gathered, and what it can and cannot support. This is a companion resource to our Beginner's Guide to Peptide Research — that guide covers how to evaluate claims; this one goes deeper into how to actually open a paper and read it productively.

Where to Find Peptide Research

Before you can read a study, you have to find one. Three resources cover most of what you need.

PubMed

PubMed is the primary database for biomedical research — maintained by the National Institutes of Health, it indexes peer-reviewed journals across medicine and life sciences. For peptide research, PubMed is the right starting point.

Search strategies for peptide-specific queries: Search for the peptide name combined with the specific outcome you want to evaluate. Examples: "BPC-157 tendon repair", "GHK-Cu collagen synthesis", "semaglutide weight loss", "TB-500 angiogenesis". Use PubMed's sidebar filters to narrow by article type — selecting "Clinical Trial" or "Randomized Controlled Trial" gives you the highest-evidence tier available. If nothing appears, that tells you something important: for most research peptides, clinical trial data in humans may not exist.

Google Scholar

Google Scholar casts a wider net, covering academic publications, preprints, theses, and technical reports that PubMed may not index. Useful for comprehensive coverage, but it requires more critical filtering — not everything indexed in Google Scholar is peer-reviewed. Check the source before interpreting a result.

ClinicalTrials.gov

ClinicalTrials.gov is the US registry for clinical trials — both ongoing and completed. It matters for peptides because a trial registration does not guarantee publication, and a lack of registered trials tells you directly that a compound has not been put through formal human evaluation. If you search for a peptide and find no registered trials, the vendor citing "promising research" is citing animal data at best.

Anatomy of a Peptide Research Paper

Most research papers follow the same structure: Abstract, Introduction, Methods, Results, Discussion, References. Here is what each section actually tells you — and what to look for critically in each.

Abstract: Don't Stop Here

The abstract is a summary — typically 150–300 words — that previews the study's purpose, methods, results, and conclusion. It is also the section most frequently read in isolation, which is how misrepresentation usually spreads.

Methods: The Most Important Section

The Methods section is where you learn whether the study can actually support its claims. Most readers skip it. That is a mistake.

Results: Data vs. Author Claims

The Results section reports the numbers — effect sizes, confidence intervals, p-values, and adverse events. This is the raw evidence. The key discipline is reading the Results independently of the Discussion: what does the data actually show, before you read the authors' interpretation of it?

Look for: the primary endpoint (what was the main outcome being measured?) and whether the treatment significantly moved it. Secondary endpoints are exploratory — positive results on secondary endpoints when the primary endpoint is negative or missing is a red flag. Also look for adverse events — if a study mentions none, check whether the follow-up period was long enough and the monitoring thorough enough to detect them.

Discussion: Interpretation vs. Evidence

The Discussion is where authors explain what they think their results mean — and where spin is most likely to appear. Authors have latitude to frame their findings positively, especially in industry-funded research. Techniques to watch for: amplifying statistically marginal results, minimizing negative secondary endpoints, speculating broadly about clinical implications from limited data, and framing preliminary findings as breakthrough evidence.

The check: does the Discussion's conclusion match the strength of evidence presented in the Results? If the results show a trend in a mouse model, the Discussion should not conclude that the treatment is effective in humans. When it does, discount the interpretation and rely on what the Results section actually reported.

Study Design Basics: What Each Level of Evidence Means

Not all studies are equal. This is the core hierarchy for evaluating peptide claims:

Where most research peptides sit: BPC-157, TB-500, GHK-Cu (injectable), CJC-1295, Ipamorelin — the evidence base is animal studies and in vitro research, with minimal human trial data. Where prescription peptides sit: Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) have extensive Phase 3 RCT data in humans. The evidential distance between these two tiers is enormous.

Key Metrics in Peptide Research

When you get past the study design and into the numbers, these are the metrics that matter most:

Concentration and Dose: In Vivo vs. In Vitro

One of the most common translation errors: a cell culture study uses a specific concentration of a peptide to produce an effect, and that concentration is used to imply a dosing protocol. The problem is that in vitro concentrations are not equivalent to in vivo doses — the distribution, metabolism, and target-tissue delivery of a compound in a living organism are completely different from its concentration in a petri dish. When a vendor cites an in vitro study to support a human dosing protocol, they are bridging a gap the evidence cannot support.

Statistical Significance

A p-value below 0.05 means the result is unlikely to be explained by random chance — the conventional threshold for statistical significance. But significance is not the same as importance. A statistically significant result can reflect a clinically trivial effect, especially in large samples. Always ask: how large is the effect, not just whether it is significant.

Effect Size

Effect size measures how large the treatment effect actually is. A Cohen's d of 0.2 is small, 0.5 is medium, 0.8 is large. Relative risk reductions can look dramatic when the base rate is low (a 50% reduction in a 2% risk is a 1-percentage-point improvement). When reading peptide research, look for absolute effect sizes on outcomes that matter — not just relative comparisons against poorly-chosen baselines.

How to Identify Conflicts of Interest

Conflicts of interest (COI) in research do not always look like fraud. The most common form is subtler: design choices, endpoint selection, and interpretation that consistently favor the sponsor's product.

In the peptide space, COI matters more than in most fields because:

• The compounds are largely unregulated — there is no FDA review process to catch biased evidence
• Vendors have direct financial incentives to produce positive results and disseminate them
• The research community for some peptides is small, with the same authors appearing repeatedly in industry-adjacent studies
• Peer review in lower-tier journals may not catch subtle design bias

How to check: Look for a "Funding" section, usually at the end of the abstract or in the Methods. Look for "Author Disclosures" or "Competing Interests" in the supplementary material. If a study discloses no funding and no disclosures, note whether the authors are affiliated with the company that manufactures the compound. Absence of disclosure is not the same as absence of COI — undisclosed COI is a documented problem in biomedical research.

The Preprint Problem

Preprints — research papers posted publicly before peer review — have become increasingly common since the COVID-19 pandemic normalized rapid scientific sharing. Platforms like bioRxiv and medRxiv host thousands of preprints in life sciences.

The problem in the peptide space: preprints are sometimes cited as if they carry the same weight as peer-reviewed publications. They do not. Peer review is imperfect, but it catches methodological errors, statistical mistakes, and unjustified interpretations that preprints do not go through. A finding in a preprint should be treated as interesting but unverified.

How to tell: Check whether the paper has a journal citation (Volume, Issue, Pages) or whether it shows a preprint server ID (bioRxiv DOI, medRxiv DOI). If a vendor cites a study, look up whether it has been published in a peer-reviewed journal or whether it is still sitting in preprint status — sometimes years after posting.

Practical Checklist: Before You Trust Any Peptide Guide or Protocol

Download the Peptide Therapy Decision Checklist

This guide covers the skill of reading studies. The Peptide Therapy Decision Checklist covers the downstream decision — once you understand the research, how do you decide whether a peptide is appropriate for your situation?

The checklist is free. It walks through: evidence tier assessment, regulatory status review, vendor quality verification, and the questions to ask before starting any research peptide protocol. Download it here — no purchase required.

For the deeper analysis of specific peptides — BPC-157, GHK-Cu, and GLP-1 — with evidence quality ratings for every major claimed benefit, see our research guides. They apply the framework in this article to the most researched peptides in each category.